Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

891 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM, van Gijn R, Schellens JH, Schot M, Lieverst J, Hillebrand MJ, Schoemaker NE, Porro MG, Beijnen JH, ten Bokkel Huinink WW. Herben VM, et al. Among authors: schellens jh. J Clin Oncol. 1999 Jun;17(6):1906-14. doi: 10.1200/JCO.1999.17.6.1906. J Clin Oncol. 1999. PMID: 10561232 Clinical Trial.
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
van Warmerdam LJ, Creemers GJ, Rodenhuis S, Rosing H, de Boer-Dennert M, Schellens JH, ten Bokkel Huinink WW, Davies BE, Maes RA, Verweij J, Beijnen JH. van Warmerdam LJ, et al. Among authors: schellens jh. Cancer Chemother Pharmacol. 1996;38(3):254-60. doi: 10.1007/s002800050479. Cancer Chemother Pharmacol. 1996. PMID: 8646800 Clinical Trial.
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM, Panday VR, Richel DJ, Schellens JH, van der Vange N, Rosing H, Beusenberg FD, Hearn S, Doyle E, Beijnen JH, ten Bokkel Huinink WW. Herben VM, et al. Among authors: schellens jh. J Clin Oncol. 1999 Mar;17(3):747-55. doi: 10.1200/JCO.1999.17.3.747. J Clin Oncol. 1999. PMID: 10071262 Clinical Trial.
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Panday VR, ten Bokkel Huinink WW, Vermorken JB, Rosing H, Koopman FJ, Swart M, Schellens JH, Beijnen JH. Panday VR, et al. Among authors: schellens jh. Pharmacol Res. 1999 Jul;40(1):67-74. doi: 10.1006/phrs.1999.0477. Pharmacol Res. 1999. PMID: 10378993 Clinical Trial.
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Meerum Terwogt JM, Malingré MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, van Tellingen O, Swart M, Schellens JH. Meerum Terwogt JM, et al. Among authors: schellens jh. Clin Cancer Res. 1999 Nov;5(11):3379-84. Clin Cancer Res. 1999. PMID: 10589748 Clinical Trial.
Phase I and pharmacokinetic study of oral paclitaxel.
Malingré MM, Terwogt JM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, Huinink WW, Swart M, Lieverst J, Schellens JH. Malingré MM, et al. Among authors: schellens jh. J Clin Oncol. 2000 Jun;18(12):2468-75. doi: 10.1200/JCO.2000.18.12.2468. J Clin Oncol. 2000. PMID: 10856107 Clinical Trial.
891 results